UM neurologist Michael Benatar was one of seven researchers that received the Sean M. Healey International Prize for Innovation in ALS at the 34th International Symposium on ALS/MND. “Our collective research...has established blood neurofilament light (NfL) as a biomarker in advancing ALS therapy development,” says Benatar.
When nerve cells die, as in ALS, neurofilament is released into the spinal fluid and blood. The amount of neurofilament in the blood reflects the speed with which neurons are dying. Researchers can use this information to guide strategies and improve the efficiency with which they work to develop new treatments. The research team included UM’s Joanne Wuu and researchers from Oxford University, Biogen, and other organizations.
View Related Expert Profiles: Go to Source
